Posts by: Jose Marques Lopes, PhD

News

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to BeiGene’s zanubrutinib as a treatment candidate for adults with mantle cell lymphoma (MCL) who have received at ... Read more

January 10, 2019

Adcetris Not Cost-effective as Second-line Therapy for Some CTCL, U.K. Board Rules

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) concluded that Adcetris (brentuximab vedotin) is not a cost-effective option when given as a second-line therapy to people ... Read more

October 2, 2018October 2, 2018

Abdominal Obesity Better Than BMI at Predicting Risk for Blood Diseases, Study Shows

News

Measuring abdominal fat (obesity), including waist circumference, is a better predictor of the risk of developing hematological malignancies, especially multiple myeloma, than body mass index (BMI), according to a ... Read more

October 1, 2018October 3, 2018

FDA Approves Copiktra Capsules for 2 Lymphoma Types, Verastem Announces

News

The U.S. Food and Drug Administration approved Copiktra (duvelisib) capsules for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a minimum of two prior ... Read more

September 13, 2018

Mouse Study Finds Potential Therapeutic Target for Anaplastic Large-cell Lymphoma

News

A cellular protein called TYK2 plays a key role in tumor development and survival in anaplastic large-cell lymphoma (ALCL), according to a new study. The finding suggests that targeting ... Read more

September 6, 2018

New Drug Application for Investigational Hodgkin’s Lymphoma Therapy Tislelizumab Accepted in China

News

China’s regulatory agency recently accepted BeiGene’s new drug application (NDA) for tislelizumab, its investigational immune checkpoint inhibitor, for the potential treatment of patients with classical Hodgkin’s lymphoma who failed to respond or whose ... Read more

July 27, 2018

BeiGene’s Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin’s Patients in Phase 2 Trial

News

BeiGene‘s immunotherapy candidate tislelizumab was shown to eliminate tumors in 50% of patients with classical Hodgkin’s lymphoma who had failed to respond to their most recent treatment, according to preliminary results of a ... Read more

July 26, 2018

Velcade-based Therapy Effective in Certain East Asian Mantle Cell Lymphoma Patients, Study Finds

News

A treatment combination including Velcade (bortezomib) was seen to be more effective than the standard R-CHOP chemotherapy in East Asian patients with mantle cell lymphoma (MCL) who cannot undergo a ... Read more

July 10, 2018

Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe

News

The European Medicines Agency (EMA) has recommended the approval of two lymphoma medications: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). The EMA’s decision represents the first two recommendations for chimeric antigen ... Read more

July 9, 2018

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

News

Sintilimab (IBI308), an immunotherapy candidate, was found to be safe and completely eliminated tumors in one-fourth of Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) treated in a Phase ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

FDA Grants Breakthrough Therapy Designation to Zanubrutinib for Mantle Cell Lymphoma

Adcetris Not Cost-effective as Second-line Therapy for Some CTCL, U.K. Board Rules

Abdominal Obesity Better Than BMI at Predicting Risk for Blood Diseases, Study Shows

FDA Approves Copiktra Capsules for 2 Lymphoma Types, Verastem Announces

Mouse Study Finds Potential Therapeutic Target for Anaplastic Large-cell Lymphoma

New Drug Application for Investigational Hodgkin’s Lymphoma Therapy Tislelizumab Accepted in China

BeiGene’s Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin’s Patients in Phase 2 Trial

Velcade-based Therapy Effective in Certain East Asian Mantle Cell Lymphoma Patients, Study Finds

Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

Pin It on Pinterest